Immune-targeted therapy and virus treatment before head and neck cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 70 years old
- Diagnosed with head and neck squamous cell carcinoma (not nasopharyngeal, salivary, or thyroid) that has spread to lymph nodes
- Your cancer is considered early stage but locally advanced (stage II, III, IVA, or IVB, depending on HPV status)
- You are able to undergo surgery to remove the tumor
- You have good overall health (ECOG score 0-1) and normal organ function
- No prior treatment with PD-1/PD-L1 or EGFR inhibitors, no active autoimmune disease, and no serious heart or lung conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This study tests a specially marked version of a drug called nivolumab (an immunotherapy that helps your immune system fight cancer) given directly into the tumor before your scheduled surgery. The goal is to help researchers see how the drug works in the tumor and whether it could improve treatment for head and neck cancer.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.